Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers

Subjects

Abstract

Sex differences exist in the neurochemical mechanisms underlying tobacco smoking and smoking-related behaviors. Men tend to smoke for the reinforcing effects of nicotine, whereas women tend to smoke for stress and mood regulation, and have a harder time maintaining long-term abstinence. The mesolimbic dopamine (DA) system drives the reinforcing effects of tobacco smoking, whereas the mesocortical DA system—including the dorsolateral prefrontal cortex (dlPFC)—is critical for stress-related cognitive functioning and inhibitory control. This study is the first to investigate dlPFC D2/3-type receptor (D2R) availability and amphetamine-induced cortical DA release in smokers and nonsmokers. Forty-nine subjects (24 tobacco smokers (12 females) and 25 sex- and age-matched nonsmokers) participated in two same-day [11C]FLB457 positron emission tomography (PET) scans before and 3-hours after amphetamine administration (0.4–0.5 mg/kg, PO). D2R availability (non-displaceable binding potential; BPND) was measured pre- and post-amphetamine. The percent fractional change in BPND (%ΔBPND) between pre- and post-amphetamine, an index of DA release, was compared between male and female smokers and nonsmokers. Smokers showed significantly lower dlPFC D2R availability (BPND = 0.77 ± 0.05) than nonsmokers (BPND = 0.92 ± 0.04), p = 0.016, driven by males. Female smokers showed significantly less amphetamine-induced DA release in dlPFC (%ΔBPND = 1.9 ± 3.0%) than male smokers (%ΔBPND = 14.0 ± 4.3%), p < 0.005, and female nonsmokers (%ΔBPND = 9.3 ± 3.3%), p < 0.005. This study shows that in the prefrontal cortex, smokers have lower D2R availability than nonsmokers and that female vs. male smokers have a blunted amphetamine-induced DA release. These findings demonstrate that tobacco smoking differentially affects the mesocortical DA system in men vs. women, suggesting a potential target for gender-specific treatments.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Center for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). US Department of Health & Human Services. 2015.

  2. 2.

    Center for Disease Control and Prevention. Drug Overdose Deaths. US Department of Health & Human Services. 2018.

  3. 3.

    Center for Disease Control and Prevention. Tobacco-Related Mortality. US Department of Health & Human Services. 2018.

  4. 4.

    Center for Disease Control and Prevention. All Injuries. US Department of Health & Human Services. 2017.

  5. 5.

    Center for Disease Control and Prevention. AIDS and HIV. US Department of Health & Human Services. 2018.

  6. 6.

    Center for Disease Control and Prevention. Alcohol and Public Health. US Department of Health & Human Services. 2018.

  7. 7.

    Perkins KA. Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharmacol. 1996;4:166–77.

  8. 8.

    Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res. 1999;1:301–15.

  9. 9.

    McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex differences in varenicline efficacy for smoking cessation: a meta-analysis. Nicotine Tob Res. 2016;18:1002–11.

  10. 10.

    McBride D, Barrett SP, Kelly JT, Aw A, Dagher A. Effects of expectancy and abstinence on the neural response to smoking cues in cigarette smokers: an fMRI study. Neuropsychopharmacology. 2006;31:2728.

  11. 11.

    Faulkner P, Petersen N, Ghahremani DG, Cox CM, Tyndale RF, Hellemann GS, et al. Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers. Psychopharmacology. 2018;235:193–202.

  12. 12.

    Xu J, Azizian A, Monterosso J, Domier CP, Brody AL, London ED, et al. Gender effects on mood and cigarette craving during early abstinence and resumption of smoking. Nicotine Tob Res. 2008;10:1653–61.

  13. 13.

    Cofta-Woerpel L, McClure JB, Li Y, Urbauer D, Cinciripini P, Wetter DW. Early cessation success or failure among women attempting to quit smoking: trajectories and volatility of urge and negative mood during the first post-cessation week. J Abnorm Psychol. 2011;120:596–606.

  14. 14.

    Smith PH, Bessette AJ, Weinberger AH, Sheffer CE, McKee SA. Sex/gender differences in smoking cessation: a review. Prev Med 2016;92:135–40.

  15. 15.

    Cosgrove KP, Esterlis I, Sandiego C, Petrulli R, Morris ED. Imaging tobacco smoking with PET and SPECT. In: Balfour JKD, Munafò RM, editors. The Neuropharmacology of Nicotine Dependence. Cham: Springer International Publishing; 2015. p. 1–17.

  16. 16.

    Benowitz NL. Nicotine addiction. New Engl J Med. 2010;362:2295–303.

  17. 17.

    Wu J, Gao M, Shen J-X, Shi W-X, Oster AM, Gutkin BS. Cortical control of VTA function and influence on nicotine reward. Biochem Pharmacol 2013;86:1173–80.

  18. 18.

    Arnsten AFT. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10:410–22.

  19. 19.

    Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12:652–69.

  20. 20.

    Arnsten AF. Stress weakens prefrontal networks: molecular insults to higher cognition. Nat Neurosci. 2015;18:1376–85.

  21. 21.

    Christoph Fehr MD, Igor Yakushev MD, Nina Hohmann DP, Hans-Georg Buchholz MS, Christian Landvogt MD, Hanna D, et al. Association of low striatal dopamine D 2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry. 2008;165:507–14.

  22. 22.

    Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry. 2011;168:634–41.

  23. 23.

    Martinez D, Gil R, Slifstein M, Hwang D-R, Huang Y, Perez A, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry. 2005;58:779–86.

  24. 24.

    Volkow ND, Chang L, Wang G-J, Fowler JS, Ding Y-S, Sedler M, et al. Low level of brain dopamine d2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry. 2001;158:2015–21.

  25. 25.

    Martinez D, Broft A, Foltin RW, Slifstein M, Hwang D-R, Huang Y, et al. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology. 2004;29:1190.

  26. 26.

    Martinez D, Saccone PA, Liu F, Slifstein M, Orlowska D, Grassetti A, et al. Deficits in dopamine D2 receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biol Psychiatry 2012;71:192–8.

  27. 27.

    Worhunsky PD, Matuskey D, Gallezot J-D, Gaiser EC, Nabulsi N, Angarita GA, et al. Regional and source-based patterns of [(11)C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D(2) and D(3) receptor availability in cocaine-use disorder. Neuroimage. 2017;148:343–51.

  28. 28.

    Brown AK, Mandelkern MA, Farahi J, Robertson C, Ghahremani DG, Sumerel B, et al. Sex differences in striatal dopamine D2/D3 receptor availability in smokers and nonsmokers. Int J Neuropsychopharmacol. 2012;15:989–94.

  29. 29.

    Okita K, Petersen N, Robertson CL, Dean AC, Mandelkern MA, London ED. Sex differences in midbrain dopamine d2-type receptor availability and association with nicotine dependence. Neuropsychopharmacology. 2016;41:2913–9.

  30. 30.

    Cosgrove KP, Wang S, Kim SJ, McGovern E, Nabulsi N, Gao H, et al. Sex differences in the brain’s dopamine signature of cigarette smoking. J Neurosci. 2014;34:16851–5.

  31. 31.

    Sudo Y, Suhara T, Inoue M, Ito H, Suzuki K, Saijo T et al. Reproducibility of [11C]FLB 457 binding in extrastriatal regions. Nucl Med Commun. 2001;22:1215–21.

  32. 32.

    Narendran R, Himes M, Mason NS. Reproducibility of Post-Amphetamine [11C]FLB 457 Binding to Cortical D2/3 Receptors. PLoS One. 2013;8:e76905.

  33. 33.

    Morris ED, Lucas MV, Cosgrove KP. How to study smoking and drinking with pet, positron emission tomography. In: Sandro Misciagna I, editor. London: IntechOpen Limited, 2013.

  34. 34.

    Arnsten AFT, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99:211–6.

  35. 35.

    Arnsten AF, Wang M, Paspalas CD. Dopamine’s actions in primate prefrontal cortex: challenges for treating cognitive disorders. Pharm Rev. 2015;67:681–96.

  36. 36.

    Perkins KA, Karelitz JL, Giedgowd GE, Conklin CA. Negative mood effects on craving to smoke in women versus men. Addict Behav. 2013;38:1527–31.

  37. 37.

    Sandiego CM, Gallezot J-D, Lim K, Ropchan J, Lin S-f, Gao H, et al. Reference region modeling approaches for amphetamine challenge studies with [11C]FLB 457 and PET. J Cereb Blood Flow Metab. 2015;35:623–9.

  38. 38.

    Sandiego CM, Matuskey D, Lavery M, McGovern E, Huang Y, Nabulsi N, et al. The effect of treatment with guanfacine, an alpha2 adrenergic agonist, on dopaminergic tone in tobacco smokers: An [11C]FLB457 PET study. Neuropsychopharmacology. 2017;43:1–7.

  39. 39.

    Beck AT. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561.

  40. 40.

    Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State‐Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press; 1970.

  41. 41.

    Patton JH, Stanford MS, Barratt ES. Factor structure of the barratt impulsiveness scale. J Clin Psychol. 1995;51:768–74.

  42. 42.

    Etter J-F, Duc TV, Perneger TV. Validity of the Fagerstrom test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Addiction. 1999;94:269–81.

  43. 43.

    Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289–94.

  44. 44.

    Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991;86:1467–76.

  45. 45.

    Narendran R, Jedema HP, Lopresti BJ, Mason NS, Gurnsey K, Ruszkiewicz J, et al. Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study. Mol Psychiatry. 2014;19:302–10.

  46. 46.

    Gaiser EC, Matuskey D, Perkins E, D’Amico C, Abdelghany O, McKee SA, et al. A case series on the heightened autonomic response due to guanfacine and amphetamine interaction. J Clin Psychopharmacol. 2015;35:197–9.

  47. 47.

    Viola P, Wells Iii WM. Alignment by maximization of mutual information. Int J Comput Vis. 1997;24:137–54.

  48. 48.

    Holmes CJ, Hoge R, Collins L, Woods R, Toga AW, Evans AC. Enhancement of MR images using registration for signal averaging. J Comput Assist Tomogr. 1998;22:324–33.

  49. 49.

    Petrides M, Pandya DN. Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns. Eur J Neurosci. 1999;11:1011–36.

  50. 50.

    Narendran R, Frankle WG, Mason NS, Rabiner EA, Gunn RN, Searle GE, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse. 2009;63:447–61.

  51. 51.

    Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.

  52. 52.

    Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279–87.

  53. 53.

    Wiers CE, Cabrera EA, Tomasi D, Wong CT, Demiral ŞB, Kim SW, et al. Striatal dopamine D2/D3 receptor availability varies across smoking status. Neuropsychopharmacology. 2017;42:2325.

  54. 54.

    Martinez D, Narendran R, Foltin R, Slifstein M, Hwang D, Broft A, et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry. 2007;164:622–9.

  55. 55.

    Busto UE, Redden L, Mayberg H, Kapur S, Houle S, Zawertailo LA. Dopaminergic activity in depressed smokers: A positron emission tomography study. Synapse. 2009;63:681–9.

  56. 56.

    Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, et al. The Relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology. 2000;22:125.

  57. 57.

    Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry. 2009;65:1091–3.

  58. 58.

    Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20:423–51.

  59. 59.

    Trifilieff P, Ducrocq F, van der Veldt S, Martinez D. Blunted dopamine transmission in addiction: potential mechanisms and implications for behavior. Semin Nucl Med. 2017;47:64–74.

  60. 60.

    Nader MA, Morgan D, Gage HD, Nader SH, Calhoun TL, Buchheimer N, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci. 2006;9:1050.

  61. 61.

    Nader MA, Daunais JB, Moore T, Nader SH, Moore RJ, Smith HR, et al. Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: initial and chronic exposure. Neuropsychopharmacology. 2002;27:35.

  62. 62.

    Perkins KA, Gerlach D, Vender J, Meeker J, Hutchison S, Grobe J. Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli. Nicotine Tob Res. 2001;3:141–50.

  63. 63.

    Perkins KA, Jacobs L, Sanders M, Caggiula AR. Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology. 2002;163:194–201.

  64. 64.

    Perkins KA, Karelitz JL. Sex differences in acute relief of abstinence-induced withdrawal and negative affect due to nicotine content in cigarettes. Nicotine Tob Res. 2015;17:443–8.

  65. 65.

    Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10:1245–50.

  66. 66.

    Arnsten AFT. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69:e89–e99.

  67. 67.

    Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105–30.

  68. 68.

    Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386:830–3.

  69. 69.

    Wu JC, Bell K, Nijafi A, Widmark C, Keator D, Tang C, et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 1997;17:402–9.

  70. 70.

    Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D 2 /D 3 receptors following acute dopamine depletion. Am J Psychiatry. 2009;166:1170–7.

  71. 71.

    Perkins KA, Grobe JE, Weiss D, Fonte C, Caggiula A. Nicotine preference in smokers as a function of smoking abstinence. Pharm Biochem Behav. 1996;55:257–63.

  72. 72.

    McFarland K, Kalivas PW. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J Neurosci. 2001;21:8655.

  73. 73.

    Nordström A-L, Olsson H, Halldin CA. PET study of D2 dopamine receptor density at different phases of the menstrual cycle. Psychiatry Res. 1998;83:1–6.

  74. 74.

    Wong DF, Broussolle EP, Wand G, Villemagne V, Dannals RF, Links JM, et al. In vivo measurement of dopamine receptors in human brain by positron emission tomography age and sex differences. Ann N Y Acad Sci. 1988;515:203–14.

  75. 75.

    Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006;59:966–74.

  76. 76.

    Mazure CM, Toll B, McKee SA, Wu R, O’Malley SS. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug Alcohol Depend. 2011;114:68–72.

  77. 77.

    Allen SS, Bade T, Center B, Finstad D, Hatsukami D. Menstrual phase effects on smoking relapse. Addiction. 2008;103:809–21.

  78. 78.

    Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev. 2011;35:565–72.

  79. 79.

    Heinrich J. GAO-01-286R. Washington, DC: ed Office USGA; 2001.

Download references

Acknowledgements

We would like to thank Jon-Michael Anderson, Erin McGovern, Evgenia Perkins, Patrick Worhunsky, and the staff at the Yale PET Center.

Author information

Correspondence to Kelly P. Cosgrove.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Sixteen of the participants in this study took part in the following clinical trial: imaging extrastriatal dopamine release in tobacco smokers and nonsmokers; NCT02348385.

Supplementary information

Supplemental Material

Supplemental Figure 1

Supplemental Figure 2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark